MedTrace Logo

First Time in Human Study Using GSK2330672

NCT01416324 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2017-06-20

No results posted yet for this study

Summary

The purpose of this study is to look at the safety and tolerability of increasing single doses of GSK2330672 in healthy volunteers.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

placebo

Vehicle used to dilute the powder for oral administration.

DRUG

0.1 mg GSK2330672

GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

DRUG

0.3 mg GSK2330672

GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

DRUG

1 mg GSK2330672

GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

DRUG

3 mg GSK2330672

GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

DRUG

10 mg GSK2330672

GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

DRUG

30 mg GSK2330672

GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

DRUG

60 mg GSK2330672

GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-15
Primary Completion
2011-09-09
Completion
2011-09-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01416324 on ClinicalTrials.gov